'Expected infarct size without thrombolysis', a concept that predicts immediate and long-term benefit from thrombolysis for evolving myocardial infarction
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Background Thrombolytic therapy should only be used when expected benefits outweigh the risks. In order to obtain a precise estimation of prognosis, with and without thrombolytic therapy, we postulated that mortality reduction by thrombolytic therapy is a function of the area of myocardium at risk for necrosis. We developed a model to estimate the myocardial area at risk for necrosis from clinical parameters readily available upon hospital admission. This model was validated in relation to long-term prognosis and benefits of thrombolytic therapy.
Methods Enzymatic infarct size with and without thrombolysis was predicted from the haemodynamic state and the electrocardiogram on hospital admission by multivariate regression analysis in 885 patients in the rt-PA placebo and rt-PA/PTCA trial of the European Cooperative Study Group. This multivariate function was used to validate the 'expected infarct size without thrombolytic treatment' in a test population of 533 patients from the Intracoronary Streptokinase trial of the Interuniversity Cardiology Institute of The Netherlands (ICIN) and 1741 patients from the Intravenous Streptokinase in Acute Myocardial Infarction (ISAM) study, both trials with a non-thrombolysed control group.
Results Expected infarct size correlated well with the actual enzymatic infarct size in the non-thrombolysed patients of the latter two series. Limitation of infarct size by thrombolytic therapy was greatest in patients with a large 'expected infarct size' and absent in patients with a small area at risk. Similarly, one year mortality reduction was greatest in patients with a large 'expected infarct size without thrombolysis'; four deaths were prevented per hundred (95% confidence interval 0 to 9) if the area at risk was large, vs one death (95% confidence interval -2 to 3) in patients with a small area at risk. Benefit was most pronounced in patients with a large area at risk who were treated early within 3 h of symptom onset. A score for the determination of 1 year mortality with and without thrombolytic therapy is presented to help the clinician determine who to treat with thrombolytic therapy.
Introduction
Limitation of infarct size, preservation of left ventricular function and improved survival after myocardial infarction have been demonstrated for various thrombolytic agents 1 '" 71 . Thrombolytic therapy is associated with a small but pertinent risk of intracranial bleeding and, therefore, clinicians should weigh benefit and risk in each individual patient' 8 " 101 . There is agreement that patients with extensive ST segment elevation, admitted within 6 h of symptoms onset, should be treated. However, when the risk for intracranial bleeding is increased, especially in patients with smaller infarcts and longer treatment delay, a more precise estimate of the benefit of thrombolytic therapy is needed'" 1 . Survival after myocardial infarction is determined by age and gender, previous infarction, the amount of ST segment elevation and haemodynamic state on admission'
12 " 2 ' 1 . To predict benefit of thrombolysis, determinants of prognosis that can be modified by thrombolytic therapy should be considered. Since mortality reduction by thrombolysis is mediated by preservation of myocardium' 5 -6221 , we postulated that mortality reduction by thrombolytic therapy is a function of the area of myocardium at risk for necrosis. The concept 'expected infarct size without thrombolysis' is introduced as an estimate for the area of myocardium at risk for necrosis. The following questions were addressed: 1. Enzymatic infarct size: can it be predicted on hospital admission using simple demographic, historical, haemodynamic and electrocardiographic criteria? 2. Is 'expected infarct size without thrombolysis' a useful composite descriptor of the risk profile in individual patients with evolving myocardial infarction? 3. Does the concept 'expected infarct size without thrombolysis' help to predict the benefits of thrombolytic therapy? A model to predict the 'expected infarct size without thrombolytic therapy' was developed from placebocontrolled data collected by the European Cooperative Study Group' 6231 and tested in two other series with a non-thrombolysed control group' 5221 . 
Design and methods

Study design
Patients with chest pain suggesting myocardial ischaemia were considered for inclusion when electrocardiographic ST-segment elevation was present on admission. Atrial fibrillation was an exclusion criterion in the ISAM trial, but not in the others. 
Electrocardiographic analysis
Electrocardiograms obtained before the start of trial medication were centrally assessed by core laboratories for ECG reading. Infarct location was determined and the ST segment deviation was measured at the J-point. The QRS width was measured in all trials except in the ICIN trial. The location of the infarction was defined as anterior if there was ST segment elevation in leads V, to V 4 , and as inferior if there was ST segment elevation in leads II, III and aVF. In the case of ST segment elevation in leads I, aVL, V 5 and V 6 , the location of the infarction was defined as anterior, unless ST segment elevation was also present in leads II, III and aVF, or ST segment depression was present in leads V, to V 4 . In the latter case, the location of the infarction was defined as inferior or (infero-posterior 
Data analysis
Prediction of enzymatic infarct size
In the trials of the European Cooperative Study Group, 885 out of 905 patients had adequate enzymatic infarct size determinations. Enzymatic infarct size was predicted by linear regression analysis using parameters that were known to be related to infarct size in order to avoid entry of variables into the prediction model just by the play of chance. The following parameters were considered: (1) Median and 50% range of enzymatic infarct size were determined in various categories of the above variables for each trial of the ECSG (Table 1) . Subsequently variables were entered in a multivariate linear regression model (BMDP software program 1R). For continuous variables, patients were subdivided into three of four subgroups of equal size in order to yield a scoring system without quadratic or logarithmic terms to describe non-linear relationships between these determinants and enzymatic infarct size. For each category except the reference category, an indicator variable was used with a value of 1 if the patient belonged to that category and zero if not. At first screening, variables were entered in a stepwise regression model if the F statistic to enter exceeded 4 and removed if the F to remove was less than 4. In the final model, indicator variables for treatment strategy and missing data were forced into the model (Table 2 ). Product terms were used when appropriate' 271 .
Calculation of 'expected infarct size without thrombolysis' in individual patients
The multivariate linear regression model for enzymatic infarct size developed in the trials of the European Cooperative Study Group (Table 2 ) was used to calculate the 'expected infarct size without thrombolysis' for every patient by setting the indicator variables for treatment to values indicative for placebo infusion. For example the 'expected infarct size without thrombolysis' for a patient with anterior infarct localization, 12 mm ST-segment deviation (1-2 mV), narrow QRS complex, no signs of heart failure is: 531+217 + 287=1035 U ( Table 2 ). This 'expected infarct size without thrombolysis' was validated in the non-thrombolysed control groups of the ICIN and ISAM trials using a likelihood ratio' 281 .
Prognostic value of 'expected infarct size without thrombolysis'
Determinants of mortality were identified univariately by assessing 1 year mortality in a subgroup of patients ( Table 4) . For risk ratios, test-based confidence intervals were given 1291 . In the stepwise regression analysis, variables were entered when the P value associated with entry of that variable was less than 010 and removed if the P-value associated with removal was greater than 015 (BMDP software program LR). Adjusted rate ratios and 95% confidence intervals in Table 5 were obtained from the logistic regression equation according to Miettinen' 301 .
'Expected infarct size without thrombolysis' and benefit of thrombolysis
In order to assess the relationship between 'expected infarct size without thrombolysis' and limitation of infarct size by thrombolytic therapy, the actual measured infarct size in both treatment groups were compared in three categories of 'expected infarct size without thrombolysis' (Fig. 1) . Analysis of variance was performed to assess the null-hypotheses that 'expected infarct size without thrombolysis' and thrombolytic therapy were not related to the actual measured infarct size and to evaluate the interaction between 'expected infarct size without thrombolysis' and thrombolytic therapy (BMDP software program 7D). Kaplan-Meier survival plots were used to study survival of patients in different categories of 'expected infarct size without thrombolysis', for patients allocated to thrombolytic therapy and controls separately (Figs 2  and 3 ) [31) . Log rank testing was applied to test the hypothesis that survival with and without thrombolytic therapy was equal in various patient subgroups in Figs 2 and 3 (BMDP software program 1L).
Results
Prediction of enzymatic infarct size
The sum of ST-segment deviation, Killip class and QRS width were strongly related to enzymatic infarct size (Table 1) . Anterior infarct location was associated with larger enzymatic infarct size than inferior infarct location, irrespective of the amount of ST-segment deviation. The determinants and their contribution to actual infarct size, as assessed by linear regression analysis, are reported in Table 2 . All these predictors had the same pattern of influence on enzymatic infarct size in both thrombolysis patients and controls. Age, gender and previous infarction were not predictive of enzymatic infarct size.
'Expected infarct size without thrombolysis' in individual patients
In Fig. 1 the median and 50% range of the actual measured enzymatic infarct size are depicted for three categories of'expected infarct size without thrombolysis' in the ICIN and ISAM trials. The enzymatic infarct size prediction model developed in the trials of the European Cooperative Study Group was successful in separating patients with small and large infarcts in these test populations. In the ICIN trial, the infarct size score was related to the actual measured infarct size (/>=000001) and thrombolytic therapy limited infarct size (/ > =000001), with evidence of a larger infarct size reduction in patients with large 'expected infarct size without thrombolytic therapy' (P=0045 for interaction according to analysis of variance). Similarly, in the ISAM trial the infarct score and treatment with thrombolytic therapy were related to the enzymatic infarct size (/>=000001 and P=004 respectively), but no evidence for interaction between infarct score and thrombolytic therapy was found (P=0-50).
Accuracy and precision were assessed in a test population consisting of 218 patients from the control group of the ICIN trial in whom enzymatic infarct size was also determined with HBDH measurements. Predicted infarct size, according to the infarct size score, overestimated the actual measured infarct size by 10% (90% range -49% to 321%). Among 73 patients with a large predicted infarct size of 1000 U . I " 1 or more, accuracy was nearly perfect (0-5% over-estimation, 90% range -4 6 % to 154%).
The diagnostic power of the concept of 'expected infarct size without thrombolysis' in detecting patients who develop large enzymatic infarctions in the control group of the ICIN and ISAM trials is illustrated in Table 3 . A value of 0-800, 800-1000 and > = 1000 U . I " 1 for 'expected infarct size without thrombolysis' was seen, respectively, 0-5, 1-2 and 2-2 times more frequently among patients with large enzymatic infarctions than among patients with small infarcts after pooling of the ICIN and the ISAM trials, without overlap of the 95% confidence intervals for these estimates. 
Prognostic value of 'expected infarct size without thrombolysis'
'Expected infarct size without thrombolysis' as predicted with the linear regression model obtained in the European Cooperative trials from the admission electrocardiogram and clinical state, was highly predictive for mortality (Table 4 ). One year mortality among patients with a small 'expected infarct size without thrombolysis' ranged from 5 to 11% in the control groups. Patients with a large 'expected infarct without thrombolysis' died in 16-26% of the cases when no thrombolytic therapy was given. Pooling the rt-PA/placebo, ICIN and ISAM data of Table 4 , a large 'expected infarct size without thrombolysis' was seen 1-8 times more frequently among the 1 year deaths than among 1 year survivors (95% confidence 1-5 to 2-2). In Fig. 2 , survival during the first 4 years of follow-up is depicted for, respectively, patients below 60 years and 60 years and older, stratified for 'expected infarct size without thrombolysis'. Survival was determined by age and 'expected infarct size without thrombolysis' (compare the four dotted lines). The results of the multivariate analysis are listed in Table 5 . 'Expected infarct size without thrombolysis' was an important determinant of mortality with a relative risk varying from 1-3 to 2-5 depending on the extent of myocardium at risk. Age of 60 years or more was associated with a 2-1 times higher mortality than age below 60 years.
Eur Heart J, Vol. 18, November 1997 CI=confidence interval. A likelihood ratio of 218 for an 'expected infarct size without thrombolysis' of > = 1000 U . 1 ~' means that such a value of 'expected infarct size without thrombolysis' was seen 2 18 times more often among patients with a large than with a small enzymatic infarct. The enzymatic infarct size was defined as large if > = the median enzymatic infarct size in the control group of each trial. Follow-up duration was less than 1 year in 16 patients. These patients were included in the analysis because all but one had at least 3 months follow-up and most deaths after myocardial infarction tend to occur within 3 months. Results are presented as percentages with the absolute numbers in parentheses.
Table 4 I year mortality in various categories of 'expected infarct size without thrombolysis' stratified for treatment delay
Patients with a previous infarction died 2-7 times more often than patients without. Female gender was associated with a 1-3-fold higher risk. Infarct location was not predictive for 1 year mortality, when 'expected infarct size without thrombolysis' was included in the model.
'Expected infarct size without thrombolysis' and benefit of thrombolysis Limitation of infarct size
In the ICIN trial, the limitation of infarct size was most pronounced in patients with large 'expected infarct size without thrombolysis'. As depicted in Fig. 1 in the low risk group with an 'expected infarct size without thrombolysis' of <800 U . I ' t h e median enzymatic infarct size was nearly identical in both treatment groups with 465 U . I" ' (50% range 292 to 814) and 426 U . 1" ' HBDH (50% range 237 to 713 U . I " 1 ) in controls and thrombolysis patients, respectively (8% infarct size reduction). In the intermediate risk group (800 to 1000 U . I " 1 'expected infarct size without thrombolysis'), infarct size reduction by thrombolytic therapy was 768 U . r ' (50% range 498 to 1223) minus 582 U . 1" ' HBDH (50% range, 331 to 868), resulting in a 35% reduction. In patients with a large 'expected infarct size without thrombolysis' >= 1000U.I" 1 the median enzymatic infarct size was 1124 U . 1"' (50% range 780 to 1484) in the control group vs 773 U . I " 1 HBDH (50% range 512 to 1200) after thrombolytic therapy. Indicator variables for thrombolytic treatment and their interaction terms with treatment delay were forced into the model and are omitted from the table. The model is designed in such a way that the reference categories refer to the placebo group in the rt-PA/placebo trial of the ECSG. Absolute numbers are in parentheses. CI=confidence interval; *adjusted risk ratio calculated according to Miettinen. Follow-up duration was less than 1 year in 16 survivors. These patients were included in the analysis because all but one had at least 3 months follow-up and most deaths after myocardial infarction tend to occur within 3 months. This corresponds to a 31% reduction in infarct size by intracoronary streptokinase. With analysis of variance a /•-value of 0-045 was found for the interaction between 'expected infarct size without thrombolysis' and thrombolytic therapy.
In the ISAM trial, a similar trend was found but there was no significant interaction between infarct size score and thrombolytic therapy (F-value 0-50). Proportional infarct size reduction was less than in the ICIN trial in all risk groups. In the low risk group median, the infarct size was 1059 U . I " 1 CK-MB (50% range 405 to 1873) among controls and 1039 U . I " 1 (50% range 415 to 1774) in thrombolysis patients (2% reduction of infarct size). In the intermediate group, these values were 1709 U . I " 1 (50% range 860 to 2536) and 1537U.1" 1 CK-MB (50% range 678 to 2339), corresponding to a 10% reduction of infarct size by intravenous streptokinase. In the high risk group, infarct size reduction was 13%, with 2074 U . I " 1 CK-MB (50% range 1109 to 2999) in the placebo group and 1808 U . r ' (50% range 938 to 2881).
Improvement of survival
Improvement of survival by thrombolytic therapy was most pronounced in patients with a large 'expected infarct size without thrombolysis' when treated within 3 h of symptom onset (Fig. 3) . Pooling the results of the rt-PA/placebo, the ICIN and the ISAM trials (Table 4) , one year mortality among patients with a small 'expected infarct size without thrombolysis' of < 1000 U . I " 1 was 7-3% among controls and 6-5% in patients treated with thrombolytic therapy (0-8 deaths prevented in the first year of follow-up per 100 patients treated with thrombolytic therapy; 95% confidence interval -1-5 to 3-1). In patients with a large 'expected infarct size without thrombolysis' > = 1000 U . I " 1 1 year mortality was, respectively, 19% and 15% (four deaths less in the first year per 100 patients treated with thrombolytic therapy; 95% confidence interval 0 to 9). Patients with a large 'expected infarct size without thrombolysis' treated within 3 h of symptom onset had most benefit, with 1 year mortality of 19% and 13% in the control and thrombolysis groups, respectively (six deaths prevented in the first year with thrombolysis than in controls; 95% confidence interval 0 to 12). The interplay between 'expected infarct size without thrombolysis', treatment delay and benefit of thrombolytic therapy is depicted in Fig. 4 . In patients treated within 3 h of onset of symptoms 1 year mortality was reduced by approximately 50%, while after 3 to 6 h, 1 year mortality was reduced by 25%. Patients with a small 'expected infarct size without thrombolysis' had little or no mortality benefit (Fig. 4) , but there was a tendency to long-term benefit of thrombolytic therapy, irrespective of age (Fig. 2) . In patients with an extensive 'expected infarct size without thrombolysis' early benefit of thrombolytic therapy was most pronounced in the elderly with 28% (70/252) 1 year mortality among controls and 20% (53/261) in the thrombolysis group (-8% deaths after thrombolysis; 95% confidence interval 0 to -15%), but this benefit disappeared after 4 years of follow-up.
Discussion
Since mortality reduction by thrombolytic therapy is mediated by the preservation of myocardium 156 - 221 , we postulated that this mortality reduction is a function of the area of myocardium at risk for necrosis. The concept 'expected infarct size without thrombolysis' was introduced as an estimate for the area of myocardium at risk for necrosis and proved to determine the prognosis after myocardial infarction and to predict the benefit of thrombolytic therapy. It is the only parameter of myocardial area at risk for necrosis that is validated in large numbers of patients and that is readily available on hospital admission without the need for high-tech equipment.
Why 'expected infarct size without thrombolysis' as intermediate parameter?
According to the present analysis, the prognosis after evolving myocardial infarction can be determined with simple demographic, historical, haemodynamic and electrocardiographic criteria on hospital admission. It should be appreciated that prognosis after myocardial infarction can be predicted either with the use of the intermediate variable 'expected infarct size without thrombolysis' or without such an intermediate par-
Although there is evidence that the number of deaths per 100 patients treated is a fixed proportion of the mortality in the control group (Fig. 4) , this proportional reduction by thrombolytic therapy might not be true for all patients. For example, it is not plausible that the prognosis determined by factors, such as age and gender, can be modified by thrombolytic therapy. In contrast, the intermediate step of 'expected infarct size without thrombolysis' represents the mode of action of thrombolytic therapy. As such, on theoretical grounds, it seems an excellent tool to assess improvement of prognosis by thrombolytic therapy. In practice, the concept of 'expected infarct size without thrombolytic therapy' proved to separate patients with and without survival benefit of thrombolytic therapy. In addition, we learned that, while early mortality reduction was most pronounced in older patients with large expected infarct size, the number of life years gained with thrombolytic therapy represented by the surface between the survival curves for thrombolysis and controls, might not be largest in this patient group due to the limited life expectancy of this subgroup (Fig. 2) .
It has been a matter of discussion whether survival curves in thrombolysis patients and controls converge, remain parallel or diverge in the long run. As is illustrated in Fig. 2 , all three patterns exist, depending on how patient groups are composed regarding demographic characteristics, the presence of previous infarction and 'expected infarct size without thrombolytic therapy'. In the end, all curves will converge since life is not eternal.
Possible criticism regarding 'expected infarct size without thrombolysis'
One could argue that the accuracy and precision of the infarct score are insufficient for decisions in individual patients. However, the accuracy was satisfactory with only 10% over-estimation of the actual infarct size by 'expected infarct size without thrombolysis'. In the high risk patients, the accuracy of the prediction score was nearly perfect, with only 0-5% over-estimation of the actual infarct size. The over-estimation in low risk patients can be explained by the fact that infarct size predicted according to the model was at least 531 U . I " 1 ( Table 2) , while actual measured infarct size was smaller in some patients.
The precision of the prediction score was not optimal. Sources lacking precision are the individual variation in the extent of coronary artery disease, the presence of collaterals and the spontaneous coronary recanalization by endogenous fibrinolysis. Thirty-two percent of patients predicted to have small infarcts ended up with large ones (Table 3) . Thirty-one percent of patients who were predicted to have large infarcts (exceeding 1000 U . I " 1 ) ended up with small ones. Nevertheless, it should be appreciated that an 'expected infarct size without thrombolysis' of 1000U.1~' or more has a likelihood ratio of 2.2 to identify patients developing large infarctions. This diagnostic power is similar to the power of generally accepted test results as 1-0-1-5 mm ST-segment depression during exercise testing for coronary artery disease 1321 . Further criticism might relate to the choice of enzyme release as a parameter of infarct size as well as the choice of determinants of infarct size. When another measure of infarct size, radionuclide left ventriculography, was used, essentially the same predictors of infarct size were found' 12I . Enzymatic infarct size was selected as a measure of infarct size because, unlike left ventriculography, it is a reliable indicator of new myocardial damage in patients with a previous infarction. Furthermore, it was available in nearly all patients' 5 ' 61 . In similar analyses of the ICIN' 121 and ISAM trials (not presented here), essentially the same predictors of enzymatic infarct size were found. Also, the relative contributions of the determinants of infarct size were very similar between the trials. Other possible predictors, such as Q-waves on the initial electrocardiogram and symptoms could not be tested because these variables were not available for all trials used in the present analyses.
Heart failure and wide QRS were determinants for 'expected infarct size without thrombolysis' as well as for 1 year mortality conditional on their effect on infarct size. When 'expected infarct size without thrombolysis' was replaced by its determinants in the model (Table 2) , the risk ratio for heart failure and wide QRS for one year mortality was greater than in a model also containing 'expected infarct size without thrombolysis'. This means that heart failure and wide QRS had implications for 1 year mortality that were related to x2-l x2-7 Figure 5 Flow chart for assessment of cardiac baseline risk (1 year mortality when no thrombolytic therapy is given) with the 95% confidence interval in parentheses. In a first step, the 'expected infarct size without thrombolysis' is scored in hundreds of U . 1 ~' HBDH, in a second step the cardiac baseline risk is determined.
pathophysiological mechanisms other than area at risk, e.g. arrhythmias, which may occur, particularly in patients with bifascicular block' 33 '. Finally, it should be noted that the concept of 'expected infarct size without thrombolytic therapy' was validated in patients treated within 6 h of symptom onset. Whether this concept also predicts clinical benefit in patients treated after 6-12 h of onset of symptoms, is not tested in this study. However, whatever the mechanism of late thrombolytic therapy may be, this benefit is likely to be larger in patients with a large amount of myocardium at risk.
Implications of this analysis for clinical practice
With Fig. 5 , the clinician can now easily make a reliable estimate of the amount of myocardium at risk and the Eur Heart J, Vol. 18. November 1997 related probability of 1 year mortality for individual patients. For example, a 44-year-old male without previous infarction presenting with 12 mm ST segment elevation in the anterior leads, a narrow QRS and without signs of heart failure would have an 'expected infarct size without thrombolysis' score of 10 (step 1). According to step 2, the associated cardiac baseline risk is 4-7% (95% confidence 2-9 to 7-7%). The mortality reduction is about 50% for treatment within 3 h of onset of symptoms and approximately 25% for treatment between 3 and 6 h (Fig. 4) . Treatment between 6 and 12 h is associated with about 12-5% mortality reduction ' 11] . Thus, if the patient was treated within 3 h, 1 year mortality would not be 4-7% but 2-4% and 23 deaths would be prevented during the first year per 1000 patients treated. This number clearly exceeds the approximate five patients with intracranial bleeding per 1000 patients treated 1 " 1 . However, when this patient arrives in hospital after 10 h, or when the intracranial bleeding risk is high due to resuscitation or a head trauma, benefits of thrombolysis are unlikely to be present. On the other hand, thrombolytic therapy is probably beneficial after 6 h treatment delay in a patient older than 60 years with a large myocardial area at risk for necrosis. This individualized approach for the selection of patients for thrombolytic therapy is outlined elsewhere 11137 ' 381 .
The above estimates of time-related treatment effect may differ between various thrombolytic treatment strategies, such as intravenous streptokinase and alteplase 1381 . However, these differences are modest and not likely to affect the decision to administer thrombolytic therapy in most patients.
Conclusion
'Expected infarct size without thrombolytic treatment' is a useful tool for clinicians to estimate the amount of myocardium at risk for necrosis in individual patients and to decide whether thrombolytic therapy is warranted. It is the only validated parameter of myocardium at risk for necrosis that is readily available for all patients with myocardial infarction and does not need high-tech equipment.
